Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

Cited by (1,000)

Items 201–300 of 1,000

1. Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer
   Hayley M. Heers, Jennifer Stanislaw, John P. Harrelson, Michael W. Lee · 2018 · European Journal of Pharmacology
2. Retrospective Analysis of Treatment Patterns and Effectiveness of Palbociclib and Subsequent Regimens in Metastatic Breast Cancer
   Jing Xi, Aabha Oza, Shana N. Thomas, Foluso Olabisi Ademuyiwa, Katherine N. Weilbaecher, Rama Suresh, Ron Bose, Mathew Amprayil Cherian, Leonel Fernando Hernandez-Aya, Ashley Elizabeth Frith et al. · 2019 · Journal of the National Comprehensive Cancer Network
3. Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
   Yen‐Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy A. Azim, Yeşim Eralp, Yoon Sim Yap, Seock‐Ah Im, Julie Rihani, Erhan Gökmen, Ahmed El Bastawisy, Nuri Karadurmuş et al. · 2024 · Journal of Clinical Oncology
4. Can EGFR be a therapeutic target in breast cancer?
   Xi‐Yin Li, Lina Zhao, Ceshi Chen, Jianyun Nie, Baowei Jiao · 2022 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
5. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
   Gabe S. Sonke, Lowell L. Hart, Mario Campone, Frans Erdkamp, Wolfgang Janni, Sunil Verma, Cristian Villanueva, Erik Hugger Jakobsen, Emilio Alba, Erik Wist et al. · 2017 · Breast Cancer Research and Treatment
6. Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
   Alexey A. Larionov · 2018 · Frontiers in Oncology
7. Targeting the Hippo Pathway for Breast Cancer Therapy
   Liqing Wu, Xiaolong Yang · 2018 · Cancers
8. Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities
   Sunil Pancholi, Ricardo Ribas, Nikiana Simigdala, Eugene F. Schuster, Joanna Nikitorowicz-Buniak, Anna Ressa, Qiong Gao, Mariana Ferreira Leal, Amandeep Bhamra, Allan M Thornhill et al. · 2020 · Oncogene
9. Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer
   Yuan Yuan, Jin Sun Lee, Susan Elaine Yost, Paul Henry Frankel, Christopher Ruel, Colt A. Egelston, Weihua Guo, Simran Padam, Aileen Tang, Norma Martínez et al. · 2021 · European Journal of Cancer
10. Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor–positive, HER2-negative Breast Cancer and Emerging Therapeutic Opportunities
    Maxwell Roger Lloyd, Laura M. Spring, Aditya Bardia, Seth A. Wander · 2021 · Clinical Cancer Research
11. Palbociclib with Letrozole in Postmenopausal Women with ER+/HER2− Advanced Breast Cancer: Hematologic Safety Analysis of the Randomized PALOMA-2 Trial
    Veronique C Dieras, Nadia Harbeck, Anil Abraham Joy, Karen A. Gelmon, Johannes Ettl, Sunil Verma, Dongrui Ray Lu, Eric Roland Gauthier, Patrick Schnell, Ave Mori et al. · 2019 · The Oncologist
12. A contemporary review of male breast cancer: current evidence and unanswered questions
    Roberto Antonio Leon-Ferre, Karthik V. Giridhar, Tina J. Hieken, Robert W. Mutter, Fergus J. Couch, Rafael E. Jiménez, John R. Hawse, Judy Caroline Boughey, Kathryn J. Ruddy · 2018 · Cancer and Metastasis Reviews
13. CDK4: a master regulator of the cell cycle and its role in cancer
    Stacey J. Baker, Poulikos I. Poulikakos, Hanna Yoko Irie, Samir Sunil Parekh, E. Premkumar Reddy · 2022 · Genes & Cancer
14. HR+, HER2– Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles
    Sarah LeNoir Sammons, Donna L. Topping, Kimberly Blackwell · 2017 · Current Cancer Drug Targets
15. Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response
    Cristina Guarducci, Martina Bonechi, Giulia Boccalini, Matteo Benelli, Emanuela Risi, Angelo Di Leo, Luca Malorni, Ilenia Migliaccio · 2017 · Breast Care
16. Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: Relief from immunosuppression is associated with clinical response
    Fabio Scirocchi, Simone Scagnoli, Andrea Botticelli, Alessandra Di Filippo, Chiara Napoletano, Ilaria Grazia Zizzari, Lidia Strigari, Federica Tomao, Enrico Cortesi, Aurelia Rughetti et al. · 2022 · EBioMedicine
17. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer
    Carla L. Alves, Sidse Ehmsen, Mikkel G. Terp, Neil Portman, Martina Tuttolomondo, Odd Lilleng Gammelgaard, Monique F. Hundebøl, Kamila K. Kaminska, Lene E. Johansen, Martin Bak et al. · 2021 · Nature Communications
18. CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
    Rossana Roncato, Jacopo Angelini, Arianna Pani, Erika Cecchin, Andrea Sartore Bianchi, Salvatore Siena, Elena De Mattia, Francesco Scaglione, Giuseppe Toffoli · 2020 · International Journal of Molecular Sciences
19. Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.
    Neven, P., Fasching, P. A., Chia, S., Jerusalem, G., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Martín, M., Nusch, A. et al. · 2023 · Breast Cancer Research
20. Role of Apelin/APJ axis in cancer development and progression
    Javad Masoumi, Abdollah Jafarzadeh, Hossein Khorramdelazad, Morteza Abbasloui, Jalal Abdolalizadeh, Najmeh Jamali · 2020 · Advances in Medical Sciences
21. PI3K/AKT/mTOR inhibitors for hormone receptor-positive advanced breast cancer
    Chunfang Hao, Yunchu Wei, Wenjing Meng, Jie Zhang, Xiaonan Yang · 2024 · Cancer Treatment Reviews
22. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective
    Rohit Ashok Mistry, Jessica R. May, Gaurav Suri, Kate C. Young, Diana I Brixner, Gary M. Oderda, JOSEPH E. BISKUPIAK, Derek H. Tang, Subrata Bhattacharyya, Dinesh Mishra et al. · 2018 · Journal of Managed Care & Specialty Pharmacy
23. Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer
    Maura N. Dickler, Cristina Saura, Donald Richards, Ian E. Krop, Andrès M.R. Cervantes, Philippe Lucien Bedard, Manish R. Patel, Lajos Pusztai, Mafalda Oliveira, Alison K. Cardenas et al. · 2018 · Clinical Cancer Research
24. Comparison of treatment-related adverse events of different Cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer: A network meta-analysis
    Alexandra Desnoyers, Michelle B. Nadler, Vikaash Kumar, Ramy Saleh, Eitan Amir · 2020 · Cancer Treatment Reviews
25. Ribociclib Bioavailability Is Not Affected by Gastric pH Changes or Food Intake: In Silico and Clinical Evaluations
    Tanay S. Samant, Shyeilla V. Dhuria, Yasong Lu, Marc Laisney, Shu Yang, Arnaud Grandeury, Martin Mueller‐Zsigmondy, Kenichi Umehara, Felix Huth, Michelle C. Miller et al. · 2017 · Clinical Pharmacology & Therapeutics
26. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor–Positive Metastatic Breast Cancer
    Jinming Li, Xingfa Huo, Fuxing Zhao, Dengfeng Ren, Raees Ahmad, Xinyue Yuan, Feng Du, Jiuda Zhao · 2020 · JAMA Network Open
27. Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience
    Seth Andrew Wander, Hyo Sook Han, Mark L. Zangardi, Andrzej Niemierko, Veronica Mariotti, Leslie SL Kim, Jing Xi, Apurva Pandey, Siobhan Dunne, Azadeh Nasrazadani et al. · 2021 · Journal of the National Comprehensive Cancer Network
28. Advances in Targeted Therapies for Triple-Negative Breast Cancer
    Kelly Elizabeth McCann, Sara Alsterlind Hurvitz, Nicholas Patrick McAndrew · 2019 · Drugs
29. CDK4/6 inhibitors in breast cancer therapy: Current practice and future opportunities
    Filipa C. Lynce, Ayesha N. Shajahan‐Haq, Sandra M. Swain · 2018 · Pharmacology & Therapeutics
30. Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives
    Chikashi Watase, Sho Shiino, Tatsunori Shimoi, Emi Noguchi, Tomoya Kaneda, Yusuke Yamamoto, Kan Yonemori, Shin Takayama, Akihiko Suto · 2021 · Cancers
31. Venous thromboembolism in breast cancer patients receiving cyclin‐dependent kinase inhibitors
    Lorenzo Gervaso, Alberto J. Montero, Xuefei Jia, Alok A. Khorana · 2019 · Journal of Thrombosis and Haemostasis
32. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors
    Hitisha Patel, Nianjun Tao, Kyung-Min Lee, Mariela Huerta-Rosario, Heike Arlt, Tara L. Mullarkey, Steven M. Troy, Carlos L. Arteaga, Teeru Bihani · 2019 · Breast Cancer Research
33. Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study
    Joe‐Elie Salem, Lee S. Nguyen, Javid J. Moslehi, Stéphane Éderhy, Bénédicte Lebrun‐Vignes, Dan M. Roden, Christian Funck‐Brentano, Paul Gougis · 2021 · European Heart Journal
34. Breast cancer treatment-induced cardiotoxicity
    Samuel Martel, Christian Maurer, Matteo Lambertini, Noam Falbel Ponde, Evandro de Azambuja · 2017 · Expert Opinion on Drug Safety
35. CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib
    Laderian, Bahar, Fojo, Tito · 2017 · Seminars in Oncology
36. CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety
    Cynthia L. Palmer, Britton W. Boras, Bernadette Pascual, Na Li, Danan Li, Scott J. Garza, Nanni H. Huser, Jing Tang Yuan, Julie A. Cianfrogna, Tae Sung et al. · 2025 · Cancer Cell
37. CDK4/6 Inhibitors in HR+/HER2- Advanced/metastatic Breast Cancer: A Systematic Literature Review of Real-World Evidence Studies
    Nadia Harbeck, Meaghan Bartlett, Dean Spurden, Becky Hooper, Lin Zhan, Emily Rosta, Chris G Cameron, Debanjali Mitra, Anna Zhou · 2021 · Future Oncology
38. Fulvestrant in advanced breast cancer: evidence to date and place in therapy
    Katalin Boér · 2017 · Therapeutic Advances in Medical Oncology
39. Clinical and molecular aspects of breast cancer: Targets and therapies
    Godone R.L.N., Glauber Moreira Leitão, Nafice Araújo, Carlos Henrique Madeiros Castelletti, José Luiz de Lima-Filho, Danyelly Bruneska Gondim Martins · 2018 · Biomedicine & Pharmacotherapy
40. Current Landscape of Targeted Therapies for Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer
    Tarah Jean Ballinger, Jason B. Meier, Valerie Malyvanh Jansen · 2018 · Frontiers in Oncology
41. CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer
    Mangala Iyengar, Patrick O’Hayer, Alex Cole, Tara Sebastian, Kun Yi Yang, Lan Gardner Coffman, Ronald J. Buckanovich · 2018 · Oncotarget
42. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer in PALOMA-3
    Massimo Cristofanilli, Angela M. DeMichele, Carla Giorgetti, Nicholas C. Turner, Dennis J. Slamon, Seock‐Ah Im, Norikazu Masuda, Shailendra Verma, Sherene Loi, Marco Angelo Colleoni et al. · 2018 · European Journal of Cancer
43. Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders
    Xuewei Wu, Xiaobao Yang, Yan Xiong, Ruitong Li, Takahiro Ito, Tamer A. Ahmed, Zoi Karoulia, Christos Adamopoulos, Hong Wang, Li Wang et al. · 2021 · Nature Cancer
44. Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trials
    Fausto Petrelli, Antonio Ghidini, Rebecca Pedersini, Mary Cabiddu, Karen Borgonovo, Maria Chiara Parati, Mara Ghilardi, Vito Amoroso, Alfredo Berruti, Sandro Barni · 2019 · Breast Cancer Research and Treatment
45. Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer
    Anishka D'souza, DARCY V. SPICER, Janice M. Lu · 2018 · Journal of Hematology & Oncology
46. Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer
    Mónica Cejuela Solís, Ana Gil-Torralvo, María Ángeles Castilla, Maria A Dominguez-Cejudo, Alejandro Falcón, Marta Benavent, Sonia Molina‐Pinelo, Manuel Ruíz-Borrego, Javier Salvador Bofill · 2023 · International Journal of Molecular Sciences
47. TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2– breast cancer
    Aditya Bardia, Komal L. Jhaveri, Kevin M. Kalinsky, Sònia Pernas, Junji Tsurutani, Binghe Xu, Erika Paige Hamilton, Seock‐Ah Im, Zbigniew Ireneusz Nowecki, Joohyuk Sohn et al. · 2023 · Future Oncology
48. Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer
    Svasti Haricharan, Nindo B. Punturi, Purba Singh, Kimberly R. Holloway, Meenakshi Anurag, Jacob L. Schmelz, Cheryl Schmidt, Jonathan Thomas Lei, Vera Jean Suman, Kelly K. Hunt et al. · 2017 · Cancer Discovery
49. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2018 edition
    Tatsunori Shimoi, Shigenori E. Nagai, Tetsuhiro Yoshinami, Masato Takahashi, Hitoshi Arioka, Mikiya Ishihara, Yuichiro Kikawa, Kei Koizumi, Naoto Kondo, Yasuaki Sagara et al. · 2020 · Breast Cancer
50. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
    Maxwell Roger Lloyd, Komal L. Jhaveri, Kevin M. Kalinsky, Aditya Bardia, Seth Andrew Wander · 2024 · Nature Reviews Clinical Oncology
51. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib
    Nusayba Ali Bagegni, Shana N. Thomas, Ning Liu, Jingqin Rosy Luo, Jeremy Hoog, DW Northfelt, Matthew Philip Goetz, Andres Forero, Mattias Bergqvist, Jakob Karén et al. · 2017 · Breast Cancer Research
52. Sulfation Pathways: Steroid sulphatase inhibition via aryl sulphamates: Clinical progress, mechanism and future prospects
    Potter, Barry V L · 2018 · Journal of Molecular Endocrinology
53. Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials
    Rola El Sayed, Lara El Jamal, Sarah El Iskandarani, Jeries Kort, Mahmoud Abdel Salam, Hazem I. Assi · 2019 · Frontiers in Oncology
54. Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
    Zhen Li, Wei Zou, Ji Zhang, Yunjiao Zhang, Qi Xu, Siyuan Li, Ceshi Chen · 2020 · Frontiers in Pharmacology
55. CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review
    Gian Luca Rampioni Vinciguerra, Maura Sonego, Ilenia Segatto, Alessandra Dall’Acqua, Andrea M. Vecchione, Gustavo Baldassarre, Barbara Belletti · 2022 · Frontiers in Oncology
56. Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial)
    Jun Masuda, Hitomi Sakai, Junji Tsurutani, Yuko Tanabe, Norikazu Masuda, Tsutomu Iwasa, Masato Takahashi, Manabu Futamura, Koji Matsumoto, Kenjiro Aogi et al. · 2023 · Journal for ImmunoTherapy of Cancer
57. ER+ metastatic breast cancer: past, present, and a prescription for an apoptosis-targeted future.
    Brett J. Rozeboom, Nandini Dey, Pradip K. De · 2019 · PubMed Central
58. Biological specificity of CDK4/6 inhibitors: dose response relationship,in vivosignaling, and composite response signature
    Erik S. Knudsen, Jack Hutcheson, Paris J. Vail, Agnieszka Katarzyna Witkiewicz · 2017 · Oncotarget
59. Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review
    Martina Silvestri, Antonio Cristaudo, Aldo Morrone, Claudia Messina, Luigi Bennardo, Steven Paul Nisticò, Maria Mariano, Norma Cameli · 2021 · Drug Safety
60. CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure
    Ana Christina Garrido-Castro, Shom Goel · 2017 · Current Breast Cancer Reports
61. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition
    Jorianne Boers, Clasina Marieke Venema, Erik F. J. de Vries, Andor W.J.M. Glaudemans, Thomas Christian Kwee, Ed M. D. Schuuring, John W.M. Martens, Sjoerd Geert Elias, Geke A.P. Hospers, Carolina Pia Schroder · 2019 · European Journal of Cancer
62. Targeting CDK4 (cyclin-dependent kinase) amplification in liposarcoma: A comprehensive review
    Tarek Assi, Joseph Gergi Kattan, Elie Rassy, Hussein Nassereddine, Fadi Farhat, Charles Honoré, Axel Le Cesne, Julien Adam, Olivier Mir · 2020 · Critical Reviews in Oncology/Hematology
63. Precision medicine in breast cancer: reality or utopia?
    Ali Bettaı̈eb, Catherine Paul, Stéphanie Plenchette, Jingxuan Shan, Lotfi Chouchane, François Ghiringhelli · 2017 · Journal of Translational Medicine
64. Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer
    Melanie Royce, Thomas Bachelot, Cristian Villanueva, Mustafa Özgüroğlu, Sérgio Jobim Azevedo, Felipe Melo Cruz, Marc Debled, Roberto Hegg, Tatsuya Toyama, Carla Isadora Falkson et al. · 2018 · JAMA Oncology
65. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor–positive HER2-negative metastatic breast cancer patients
    Emmanuelle Jacquet, Audrey Lardy-Cléaud, Barbara Pistilli, Sophie Franck, Paul Henri Cottu, Suzette Delaloge, Marc Debled, Laurence Vanlemmens, Marianne Leheurteur, Anne‐Valérie Guizard et al. · 2018 · European Journal of Cancer
66. Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer
    Vassilis Aggelis, Stephen R.D. Johnston · 2019 · Drugs
67. Cyclin-dependent kinase activity is required for type I interferon production
    Oya Cingöz, Stephen P. Goff · 2018 · Proceedings of the National Academy of Sciences
68. Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment
    Ying Chao Ji, Xiangsheng Liu, Juan Li, Xiaodong Xie, Max Tze-Han Huang, Jinhong Jiang, Yu‐Pei Liao, Timothy R. Donahue, Huan Meng · 2020 · Nature Communications
69. CDK8 maintains stemness and tumorigenicity of glioma stem cells by regulating the c-MYC pathway
    Kazuya Fukasawa, Takuya Kadota, Tetsuhiro Horie, Kazuya Tokumura, Ryuichi Terada, Yuka Kitaguchi, Gyujin Park, Shinsuke Ochiai, Sayuki Iwahashi, Yasuka Okayama et al. · 2021 · Oncogene
70. Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry
    Volkmar Müller, Naiba Nabieva, Lothar Häberle, Florin‐Andrei Taran, Andreas Daniel Hartkopf, Bernhard Volz, Friedrich Overkamp, Anna Lisa Brandl, Hans‐Christian Kolberg, Peyman Hadji et al. · 2017 · The Breast
71. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial
    Gabriel N. Hortobágyi · 2018 · Breast Cancer Research
72. Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer
    Claudette Falato, Francesco Schettini, Tomás Pascual, Fara Brasó‐Maristany, Aleix Prat · 2022 · Cancer Treatment Reviews
73. ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing
    Konstantinos Venetis, Francesco Pepe, Carlo Pescia, Giulia Cursano, Carmen Criscitiello, Chiara Frascarelli, Eltjona Mane, Gianluca Russo, Beatrice Taurelli Salimbeni, Giancarlo Troncone et al. · 2023 · Cancer Treatment Reviews
74. Emerging therapies for breast cancer
    Xichun Hu, Wei Huang, Minhao Fan · 2017 · Journal of Hematology & Oncology
75. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials
    Carlo G. M. Messina, Carlo Cattrini, Giulia Buzzatti, Luigi Cerbone, Elisa Zanardi, Marco Messina, Francesco Boccardo · 2018 · Breast Cancer Research and Treatment
76. Prognostic characteristics in hormone receptor-positive advanced breast cancer and characterization of abemaciclib efficacy
    Di Leo, Angelo, O’Shaughnessy, Joyce, Sledge, George W., Martin, Miguel, Lin, Yong, Frenzel, Martin, Hardebeck, Molly C., Smith, Ian C., Llombart-Cussac, Antonio, Goetz, Matthew P. et al. · 2018 · npj Breast Cancer
77. CDK6 Inhibition: A Novel Approach in AML Management
    Iris Z. Uras, Veronika Sexl, Karoline Kollmann · 2020 · International Journal of Molecular Sciences
78. The oncogenic roles and clinical implications of YAP/TAZ in breast cancer
    Juan Luo, Hailin Zou, Yibo Guo, Tongyu Tong, Yun Chen, Yunjun Xiao, Yihang Pan, Peng Li · 2023 · British Journal of Cancer
79. Selecting the optimal position of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer – the SONIA study: study protocol for a randomized controlled trial
    Annemiek van Ommen‐Nijhof, Inge R. H. M. Konings, Clementine J.J. van Zeijl, Carin A. Uyl‐de Groot, Vincent van der Noort, Agnes Jager, Gabe S. Sonke · 2018 · BMC Cancer
80. Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer
    Erin R. Scheidemann, Ayesha N. Shajahan‐Haq · 2021 · International Journal of Molecular Sciences
81. Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer
    Marios Papadimitriou, Anastasia Pazaiti, Konstantinos Iliakopoulos, Mariam Markouli, Vasiliki Michalaki, CHRISTOS A. PAPADIMITRIOU · 2022 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
82. Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives
    Rafael Caparica, Matteo Lambertini, Noam Falbel Ponde, Debora Fumagalli, Evandro de Azambuja, Martine J Piccart · 2019 · Therapeutic Advances in Medical Oncology
83. Olaparib for the treatment of breast cancer
    Gaia Griguolo, Maria Vittoria Dieci, Valentina Guarneri, PierFranco Conte · 2018 · Expert Review of Anticancer Therapy
84. The Role of CDK4/6 Inhibitors in Breast Cancer
    Conleth G. Murphy · 2019 · Current Treatment Options in Oncology
85. The era of high-quality chemical probes
    Marco P. Licciardello, Paul Workman · 2022 · RSC Medicinal Chemistry
86. The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition
    Mitsuo Terada, Aki Ito, Yuichiro Kikawa, Kei Koizumi, Yoichi Naito, Tatsunori Shimoi, Mikiya Ishihara, Takashi Yamanaka, Yukinori Ozaki, Fumikata Hara et al. · 2023 · Breast Cancer
87. Evolution of Targeted Therapy in Breast Cancer: Where Precision Medicine Began
    Jane Lowe Meisel, Vyshak Alva Venur, Michael Gnant, LA Carey · 2018 · American Society of Clinical Oncology Educational Book
88. Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)
    Nadia Harbeck, Fabio Andre Franke, Rafael Villanueva-Vázquez, Yen‐Shen Lu, Debu Tripathy, Louis WC Chow, Govind K Babu, Young‐Hyuck Im, David Chandiwana, Anil Gaur et al. · 2020 · Therapeutic Advances in Medical Oncology
89. Potential Prospect of CDK4/6 Inhibitors in Triple-Negative Breast Cancer
    Ye Hu, Jiyue Gao, Meiling Wang, Man Li · 2021 · Cancer Management and Research
90. Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2− metastatic breast cancer in the US real-world setting
    Hope S. Rugo, Rachel M. Layman, Filipa C. Lynce, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron Benjamin Cohen, Melissa Estévez, Giuseppe Curigliano, Adam Brufsky · 2025 · ESMO Open
91. Targeting CDK4/6 in breast cancer
    Anusha Shanabag, Jessica Armand, Eugene Son, Hee Won Yang · 2025 · Experimental & Molecular Medicine
92. Progress in targeted therapy for breast cancer
    Jie Ju, An‐Jie Zhu, Peng Yuan · 2018 · Chronic Diseases and Translational Medicine
93. Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies
    Joseph A. Caruso, Mylinh T. Duong, Jason P.W. Carey, Kelly K. Hunt, Khandan Keyomarsi · 2018 · Cancer Research
94. Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
    Meritxell Bellet, Faten Ahmad, Rafael Villanueva-Vázquez, Carolina Valdivia, Julián Palomino-Doza, Ada I. Ruiz, Xavier González, Encarna Adrover, Analía Azaro, Maria Valls-Margarit et al. · 2019 · Therapeutic Advances in Medical Oncology
95. Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial
    Wallwiener, Markus, Matthies, Lina, Simoes, Elisabeth, Keilmann, Lucia, Hartkopf, Andreas D, Sokolov, Alexander N, Walter, Christina B, Sickenberger, Nina, Wallwiener, Stephanie, Feisst, Manuel et al. · 2017 · Journal of Medical Internet Research
96. Combinatorial drug therapy in cancer - New insights
    Karanpreet Singh Bhatia, Bhumika, Asmita Das · 2020 · Life Sciences
97. Targeted Therapy for Premenopausal Women with HR+, HER2− Advanced Breast Cancer: Focus on Special Considerations and Latest Advances
    Aditya Bardia, Sara Alsterlind Hurvitz · 2018 · Clinical Cancer Research
98. Updates in the Evaluation and Management of Breast Cancer
    Ciara Catherine O'Sullivan, Charles L. Loprinzi, Tufia C. Haddad · 2018 · Mayo Clinic Proceedings
99. Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper
    Nicolò Matteo Luca Battisti, Nienke A. de Glas, Mina S. Sedrak, Kah Poh Loh, Gabor Istvan Liposits, Enrique Soto‐Pérez‐de‐Celis, Jessica L. Krok‐Schoen, Ines B. Menjak, Alistair E. Ring · 2018 · Therapeutic Advances in Medical Oncology
100. CDK4/6 inhibition in early and metastatic breast cancer: A review
     Anne F. de Groot, Chantal C. H. J. Kuijpers, Judith R. Kroep · 2017 · Cancer Treatment Reviews